1. Show article details.

    Lilly gets FDA approval for Alzheimer's diagnostic agent

    MarketWatch – 8:17 AM ET 05/29/2020

    Shares of Eli Lilly& Co. gained 0.8% in premarket trading on Friday, the day after the Food and Drug Administration approved Tauvid, a drug used to help diagnose tau neurofibrillary tangles in people suspected of having Alzheimer's disease. The diagnostic agent is injected into those patients, who then undergo a positron emission tomography scan. "This is the first drug approved for imaging tau pathology, one of the two neuropathological hallmarks of Alzheimer's disease, and...

  2. Show article details.

    BRIEF-Lilly Receives FDA Approval Of Tauvid For Patients Being Evaluated For Alzheimer's Disease

    Reuters – 7:54 PM ET 05/28/2020

    Eli Lilly and Co (LLY): * LILLY RECEIVES U.S. FDA APPROVAL OF TAUVID™ FOR USE IN PATIENTS BEING EVALUATED FOR ALZHEIMER'S DISEASE. * AVAILABILITY OF TAUVID WILL INITIALLY BE LIMITED AND WILL EXPAND IN RESPONSE TO COMMERCIAL DEMAND AND PAYOR REIMBURSEMENT Source text for Eikon: Further company coverage:

  3. Show article details.

    Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease

    PR Newswire – 7:17 PM ET 05/28/2020

    INDIANAPOLIS, May 28, 2020  TAUVID™, a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease.1 A neuropathological diagnosis of AD requires the demonstration of...

  4. Show article details.

    BRIEF-FDA Approves First Drug To Image Tau Pathology In Patients Being Evaluated For Alzheimer's Disease

    Reuters – 6:17 PM ET 05/28/2020

    Food and Drug Administration: * FDA APPROVES FIRST DRUG TO IMAGE TAU PATHOLOGY IN PATIENTS BEING EVALUATED FOR ALZHEIMER'S DISEASE. * U.S. FDA SAYS IT GRANTED APPROVAL OF TAUVID TO AVID RADIOPHARMACEUTICALS. * U.S. FDA SAYS TAUVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR ADULT PATIENTS WITH COGNITIVE IMPAIRMENT BEING EVALUATED FOR ALZHEIMER'S DISEASE Source text for Eikon:

  5. Show article details.

    U.S. FDA approves Eli Lilly's diagnostic agent for Alzheimer's disease

    Reuters – 6:10 PM ET 05/28/2020

    The U.S. Food and Drug Administration on Thursday approved drugmaker Eli Lilly and Co's (LLY) radioactive compound to detect tau, an important characteristic of Alzheimer's disease. Abnormal versions of two proteins, amyloid and tau, are involved in Alzheimer's disease and considered hallmarks of the brain-wasting disease.

  6. Show article details.

    Antibody drug tech firm AbCellera raises $105 million as it works on COVID-19

    Reuters – 5:00 AM ET 05/27/2020

    Canadian drug discovery technology company AbCellera, which analyzes and identifies antibodies for pharmaceutical companies working on a coronavirus treatment and other medicines, said on Wednesday it had raised $105 million in funds.

  7. Show article details.

    Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model

    PR Newswire – 5:51 PM ET 05/26/2020

    INDIANAPOLIS, May 26, 2020 President Donald J. Trump and Seema Verma, Administrator for the Centers for Medicare & Medicaid Services, today announced details of the new Part D Senior Savings Model that will allow people in the Medicare Part D program to buy their monthly prescription of insulin for no more than $35 starting January 1, 2021.

  8. Show article details.

    Lilly, Junshi Biosciences plan to start human trials of COVID-19 antibody in Q2

    Reuters – 10:22 AM ET 05/26/2020

    Shanghai Junshi Biosciences Co Ltd said on Tuesday it plans to start clinical studies to test its experimental antibody against COVID-19 in the United States and China in the second quarter of the year, with partner Eli Lilly and Co. Lilly and several other drugmakers such as Gilead Sciences (GILD), Pfizer Inc (PFE) and Merck & Co Inc (MRK) are racing to develop treatments or vaccines for the fast-spreading respi...

  9. Show article details.

    Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences’ COVID-19 Neutralizing Antibodies

    GlobeNewswire – 10:10 AM ET 05/26/2020

    Junshi Biosciences a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the publication of research results from the Company’s efforts to generate therapeutic COVID-19 neutralizing antibodies.

  10. Show article details.

    Lilly, Junshi Biosciences to start human trials of COVID-19 antibodies

    Reuters – 9:37 AM ET 05/26/2020

    Shanghai Junshi Biosciences Co Ltd said on Tuesday it planned to start clinical studies to test its experimental COVID-19 antibodies, developed with partner Eli Lilly and Co (LLY), by the second quarter of the year in the United States and China.

  11. Show article details.

    BRIEF-Boehringer Ingelheim and Lilly To Collaborate With Duke Clinical Research Institute On A Pragmatic Trial

    Reuters – 9:19 AM ET 05/26/2020

    Eli Lilly and Co (LLY): * BOEHRINGER INGELHEIM AND LILLY TO COLLABORATE WITH DUKE CLINICAL RESEARCH INSTITUTE ON A PRAGMATIC TRIAL EXAMINING JARDIANCE'S® EFFECTS FOLLOWING AN ACUTE MYOCARDIAL INFARCTION. * ELI LILLY (LLY) - RANDOMIZED CLINICAL TRIAL TO BE CONDUCTED, ANALYZED, REPORTED IN PARTNERSHIP WITH DCRI, WITH BOEHRINGER INGELHEIM AND CO PROVIDING FUNDING Source text for Eikon: Further company coverage:

  12. Show article details.

    Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance's® effects following an acute myocardial infarction

    PR Newswire – 8:00 AM ET 05/26/2020

    RIDGEFIELD, Conn. and INDIANAPOLIS, May 26, 2020 Boehringer Ingelheim and Eli Lilly and Company (LLY) today announced an academic research collaboration with the Duke Clinical Research Institute on a new trial, EMPACT-MI. The collaboration will investigate whether Jardiance® can improve outcomes and prevent heart failure in adults with and without diabetes who have had an acute myocardial infarction,...

  13. Show article details.

    BRIEF-Emgality Shows Improvement In Work Productivity And Health And Well-Being Between Attacks In Patients With Migraine And A History Of Preventive Treatment Failure

    Reuters – 7:43 AM ET 05/26/2020

    Eli Lilly and Co (LLY): * EMGALITY® SHOWS IMPROVEMENT IN WORK PRODUCTIVITY AND HEALTH AND WELL-BEING BETWEEN ATTACKS IN PATIENTS WITH MIGRAINE AND A HISTORY OF PREVENTIVE TREATMENT FAILURE. * Eli Lilly and Co (LLY) - AMONG 462 PATIENTS RANDOMIZED TO EMGALITY OR PLACEBO, STATISTICALLY SIGNIFICANT IMPROVEMENTS IN WORK PRODUCTIVITY Source text for Eikon: Further company coverage:

  14. Show article details.

    Emgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure

    PR Newswire – 6:45 AM ET 05/26/2020

    INDIANAPOLIS, May 26, 2020 Emgality® significantly improved work productivity and reduced interictal burden, defined as health and well-being between migraine attacks, in an analysis of the 3-month double-blind period of the CONQUER study, which included patients with migraine from 12 different countries.

  15. Show article details.

    BRIEF-Abcellera Announces Multi-Year Antibody Discovery Collaboration With Lilly

    Reuters – 5:47 PM ET 05/22/2020

    Abcellera: * ABCELLERA ANNOUNCES MULTI-YEAR ANTIBODY DISCOVERY COLLABORATION WITH LILLY. * ABCELLERA - HAS ENTERED INTO MULTI-YEAR STRATEGIC RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH ELI LILLY. * ABCELLERA - UNDER TERMS, CO RECEIVED UP-FRONT PAYMENT & WILL RECEIVE RESEARCH PAYMENTS FOR NON-COVID-19 TARGETS Source text for Eikon: Further company coverage:

  16. Show article details.

    BRIEF-Avidity Biosciences Files For IPO Of Upto $100 Million

    Reuters – 4:33 PM ET 05/22/2020

    Avidity Biosciences Inc: * AVIDITY BIOSCIENCES INC FILES FOR IPO OF UPTO $100 MILLION - SEC FILING. * AVIDITY BIOSCIENCES INC SAYS APPLIED TO LIST COMMON STOCK ON THE NASDAQ GLOBAL MARKET UNDER THE SYMBOL "RNA" * AVIDITY BIOSCIENCES INC SAYS COWEN, SVB LEERINK, CREDIT SUISSE AND WELLS FARGO SECURITIES ARE AMONG UNDERWRITERS TO THE IPO.

  17. Show article details.

    BRIEF-Eli Lilly - Study Results Demonstrate Societal Cost Burden During Early Stages Of Alzheimer's Disease

    Reuters – 9:02 AM ET 05/19/2020

    Eli Lilly and Co (LLY): * RESULTS OF GERAS-US STUDY DEMONSTRATE SOCIETAL COST BURDEN FOR PATIENTS AND CAREGIVERS DURING EARLY STAGES OF ALZHEIMER'S DISEASE Source text for Eikon: Further company coverage:

  18. Show article details.

    Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During Early Stages of Alzheimer's Disease

    PR Newswire – 9:00 AM ET 05/19/2020

    INDIANAPOLIS, May 19, 2020  Eli Lilly and Company (LLY) announced baseline results from the GERAS-US Study examining the societal costs associated with mild cognitive impairment, mild dementia, and caring for someone with Alzheimer's disease.

  19. Show article details.

    Gilead to end coronavirus drug trials, adding to access worry -researchers

    Reuters – 3:51 PM ET 05/15/2020

    Gilead Sciences Inc's (GILD) two clinical studies of its potential coronavirus treatment remdesivir will wind down by the end of May, closing off a path of patient access to the antiviral medication, according to U.S. researchers involved in the studies. The drug was given emergency use authorization by the U.S. Food and Drug Administration on May 1, but hospitals are concerned about access.

  20. Show article details.

    BRIEF-Adage Capital Partners Dissolves Share Stake In 3M, Twitter; Ups Stake in Citigroup and Goldman Sachs

    Reuters – 12:24 PM ET 05/15/2020

    ADAGE CAPITAL PARTNERS GP LLC: * ADAGE CAPITAL PARTNERS GP LLC DISSOLVES SHARE STAKE IN 3M CO - SEC FILING. * ADAGE CAPITAL PARTNERS GP LLC CUTS SHARE STAKE IN BOEING BY 41.5% TO 382,670 SHARES. * ADAGE CAPITAL PARTNERS GP LLC UPS SHARE STAKE IN CITIGROUP BY 46.1% TO 3.8 MILLION COMMON SHARES. * ADAGE CAPITAL PARTNERS GP LLC DISSOLVES SHARE STAKE IN OCCIDENTAL PETROLEUM.

Page:

Today's and Upcoming Events

  • Jul
    30

    LLY to announce Q2 earnings (Confirmed)

Past Events (last 90 days)

  • May
    14

    LLY ex-Dividend for $0.74 on 05/14/2020

    • Announce Date: 05/04/2020
    • Record Date: 05/15/2020
    • Pay Date: 06/10/2020
  • Apr
    23

    LLY announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.